Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:986095.
doi: 10.1155/2015/986095. Epub 2015 Jan 18.

High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer

Affiliations

High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer

Minjie Huang et al. Dis Markers. 2015.

Abstract

Objective: The aim of this study was to investigate the expression of Prominin-1 (CD133) in cancer cells and its potential value as a prognostic indicator of survival in patients with non-small cell lung cancer (NSCLC).

Methods: Cancerous tissues and matched normal tissues adjacent to the carcinoma from 239 NSCLC patients were obtained immediately after surgery. Immunohistochemistry of tissue microarrays was used to characterize the expression of CD133 in NSCLC and adjacent tissues. The correlation of CD133 expression with clinical characteristics and prognosis was determined by statistical analysis.

Results: CD133 protein expression levels in both the cytoplasm and nucleus were significantly higher in NSCLC tissues compared with corresponding peritumoral tissue (P < 0.05). CD133 expression in the nucleus of NSCLC cells was related to tumor diameter (P = 0.027), tumor differentiation (P < 0.001), and TNM stage (P = 0.007). Kaplan-Meier survival and Cox regression analyses revealed that high CD133 expression in the nucleus was an independent predictor of poor prognosis of NSCLC, as was high cytoplasmic CD133 expression (P < 0.001).

Conclusion: Our findings provide the first evidence that high expression of CD133 in both the nucleus and cytoplasm is associated with poor prognosis in NSCLC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative patterns of CD133 protein expression in NSCLC and normal lung tissue. (a1) and (a2) Adenocarcinoma tissue and adjacent normal lung tissue. The expression of CD133 in tumor tissue was higher than that in adjacent normal lung tissue by IHC staining. The red arrow indicates positive CD133 protein expression in the nucleus of adenocarcinoma cells. The green arrow indicates strong CD133 staining in the cytoplasm of tumor cells. (b1) and (b2) Squamous cell carcinoma of the lung. The expression of CD133 protein was positive in lung carcinoma tissues. The red arrow indicates positive CD133 protein expression in the nucleus of tumor cells. (c1) and (c2) Squamous cell carcinoma of the lung. The green arrow indicates CD133 staining in the cytoplasm of tumor cells. (d1) and (d2) Normal lung tissue. The expression of CD133 protein was negative in both the cytoplasm and nucleus. The yellow arrow indicates that expression of CD133 in alveolar epithelial cells is negative.
Figure 2
Figure 2
Kaplan-Meier survival curves following surgical therapy in NSCLC. (a) Patients with high CD133 expression in the nucleus of tumor cells (green line) exhibited significantly poorer survival compared with the low or no expression group (blue line). (b) Patients with high CD133 expression in the cytoplasm of tumor cells (green line) exhibited significantly poorer survival compared with the low or no expression group (blue line).

Similar articles

Cited by

References

    1. Sugimura H., Nichols F. C., Yang P., et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Annals of Thoracic Surgery. 2007;83(2):409–418. doi: 10.1016/j.athoracsur.2006.08.046. - DOI - PubMed
    1. Lin G., Li Y., Chen S., Jiang H. Integrated Chinese-Western therapy versus western therapy alone on survival rate in patients with non-small-cell lung cancer at middle-late stage. Journal of Traditional Chinese Medicine. 2013;33(4):433–438. doi: 10.1016/S0254-6272(13)60144-2. - DOI - PubMed
    1. Gao W., Liu L., Lu X., Shu Y. Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clinical Lung Cancer. 2011;12(1):14–17. doi: 10.3816/clc.2011.n.001. - DOI - PubMed
    1. Smith C. B., Kelley A. S., Meier D. E. Evidence for new standard of care in non-small cell lung cancer patients. Seminars in Thoracic and Cardiovascular Surgery. 2010;22(3):193–194. doi: 10.1053/j.semtcvs.2010.10.002. - DOI - PubMed
    1. Minuti G., D'Incecco A., Landi L., Cappuzzo F. Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opinion on Pharmacotherapy. 2014;15(9):1203–1213. doi: 10.1517/14656566.2014.909412. - DOI - PubMed

Publication types

MeSH terms